share_log

Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development

Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development

Aurinia Pharmaceuticals | 8-K:Aurinia Pharmicals 公佈了 2024 年第三季度和九個月的財務和經營業績,宣佈進行戰略重組,以進一步關注 LUPKYNIS® 的持續增長和 AUR200 的發展
美股SEC公告 ·  2024/11/07 19:18
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息